Identification of interleukin-2 for imaging atherosclerotic inflammation

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 2, 2006, Pages 111-116

  Fayad, Zahi A ^a   Amirbekian, Vardan ^b,c   Toussaint, Jean François ^d   Fuster, Valentin ^e  

^a Marie Josee and Henry R Kravis Center for Cardiovascular Health   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Sarnoff Endowment for Cardiovascular Science   (United States)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; TECHNETIUM 99M; TRACER;

ATHEROSCLEROSIS; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; IMMUNOPATHOLOGY; INFLAMMATION; INTRAVASCULAR ULTRASOUND; ISOTOPE LABELING; MOLECULAR IMAGING; NONHUMAN; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEIN ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ATHEROSCLEROSIS; HUMANS; INFLAMMATION; INTERLEUKIN-2; MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; RISK; TECHNETIUM;

EID: 31444452740     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1981-y     Document Type: Note

References (60)

1. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-42
2. Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: biology. Lancet 1999;353(Suppl 2):SII5-9
3. AHA. Heart disease and stroke statistics - 2005 update. Accessed 04 Jan 2005 http://www.americanheart.org/downloadable/heart/ 1103829139928HDSStats2005Update.pdf. American Heart Association
4. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001;104:2158-63
5. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997;336:1276-82
6. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000;20:1262-75
7. Kragel AH, Reddy SG, Wittes JT, Roberts WC. Morphometric analysis of the composition of atherosclerotic plaques in the four major epicardial coronary arteries in acute myocardial infarction and in sudden coronary death. Circulation 1989;80:1747-56
8. Virmani R, Burke A, Farb A. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. Eur Heart J 1998;19:678-80
9. Choudhury RP, Fuster V, Fayad ZA. Molecular, cellular and functional imaging of atherothrombosis. Nature Rev Drug Discov 2004;3:913-25
10. Tsimikas S, Palinski W, Halpern SE, Yeung DW, Curtiss LK, Witztum JL. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. J Nucl Cardiol 1999;6:41-53
11. Tsimikas S, Shortal BP, Witztum JL, Palinski W. In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscler Thromb Vasc Biol 2000;20:689-97
12. Tsimikas S. Noninvasive imaging of oxidized low-density lipoprotein in atherosclerotic plaques with tagged oxidation-specific antibodies. Am J Cardiol 2002;90:L22-L27
13. Torzewski M, Shaw PX, Han KR, Shortal B, Lackner KJ, Witztum JL, et al. Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Arterioscler Thromb Vasc Biol 2004;24:2307-12
14. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95
15. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci U S A 1995;92:8264-8
16. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26
17. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983;50:127-34
18. Ohtsuki K, Hayase M, Akashi K, Kopiwoda S, Strauss HW. Detection of monocyte chemoattractant protein-1 receptor expression in experimental atherosclerotic lesions: an autoradiographic study. Circulation 2001;104:203-8
19. Bjorkerud S, Bjorkerud B. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Am J Pathol 1996;149:367-80
20. Geng YJ, Henderson LE, Levesque EB, Muszynski M, Libby P. Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997;17:2200-8
21. Kolodgie FD, Petrov A, Virmani R, Narula N, Verjans JW, Weber DK, et al. Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V: a technique with potential for noninvasive imaging of vulnerable plaque. Circulation 2003;108:3134-9
22. Kietselaer BL, Reutelingsperger CP, Heidendal GA, Daemen MJ, Mess WH, Hofstra L, et al. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med 2004;350:1472-3
23. Carrió I, Pieri PL, Narula J, Prat L, Riva P, Pedrini L, et al. Noninvasive localization of human atherosclerotic lesions with indium 111-labeled monoclonal Z2D3 antibody specific for proliferating smooth muscle cells. J Nucl Cardiol 1998;5:551-7
24. Fleiner M, Kummer M, Mirlacher M, Sauter G, Cathomas G, Krapf R, et al. Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis. Circulation 2004;110:2843-50
25. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A 2003;100:4736-41
26. Kumamoto M, Nakashima Y, Sueishi K. Intimal neovascularization in human coronary atherosclerosis: its origin and pathophysiological significance. Hum Pathol 1995;26:450-6
27. Matter CM, Schuler PK, Alessi P, Meier P, Ricci R, Zhang D, et al. Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ Res 2004;95:1225-33
28. 18F-FDG PET/CT. J Nucl Med 2004;45:1816-21
29. 18F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med 2004;45:1245-50
30. Tawakol A, Migrino RQ, Hoffmann U, Abbara S, Houser S, Gewirtz H, et al. Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol 2005;12:294-301
31. Mochizuki Y, Fujii H, Yasuda S, Nakahara T, Takahashi W, Ide M, et al. FDG accumulation in aortic walls. Clin Nucl Med 2001;26:68-9
32. Yun M, Yeh D, Araujo LI, Jang S, Newberg A, Alavi A. F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med 2001;26:314-9
33. Machac J, Nunez R, Chen WT, Macapinlac HA. The relation of F-18 FDG uptake in human thoracic aortas and risk factors for CAD [abstract]. J Nucl Med 2002;43:190P
34. 18F]- fluorodeoxyglucose positron emission tomography. Circulation 2002;105:2708-11
35. Tatsumi M, Cohade C, Nakamoto Y, Wahl RL. Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. Radiology 2003;229:831-37
36. 18FDG PET: illusion or reality? A critical review of the literature data. Eur J Nucl Med Mol Imaging 2003;30:1305-13
37. 18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging 2005;32:674-81
38. Lipinski MJ, Fuster V, Fisher EA, Fayad ZA. Targeting of biological molecules for evaluation of high-risk atherosclerotic plaques with magnetic resonance imaging. Nature Clin Pract Cardiovasc Med 2004;1:48-55
39. Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 2004;126:16316-7
40. Varner JA, Brooks PC, Cheresh DA. REVIEW: the integrin alpha V beta 3: angiogenesis and apoptosis. Cell Adhes Commun 1995;3:367-74
41. Hoshiga M, Alpers CE, Smith LL, Giachelli CM, Schwartz SM. Alpha-v beta-3 integrin expression in normal and atherosclerotic artery. Circ Res 1995;77:1129-35
42. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64
43. Eliceiri BP, Cheresh DA. The role of alphav integrins during angiogenesis. Mol Med 1998;4:741-50
44. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 2003;108:2270-4
45. Anderson SA, Rader RK, Westlin WF, Null C, Jackson D, Lanza GM, et al. Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med 2000;44:433-9
46. Kerwin W, Hooker A, Spilker M, Vicini P, Ferguson M, Hatsukami T, et al. Quantitative magnetic resonance imaging analysis of neovasculature volume in carotid atherosclerotic plaque. Circulation 2003;107:851-6
47. Sirol M, Itskovich VV, Mani V, Aguinaldo JG, Fallon JT, Misselwitz B, et al. Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation 2004;109:2890-6
48. Fuster V. [Thrombus remodeling. Key factor in the progression of coronary atherosclerosis]. Rev Esp Cardiol 2000;53 Suppl 1:2-7
49. Sirol M, Aguinaldo JGS, Graham G, et al. Fibrin-targeted contrast agent for improvement of in vivo acute thrombus detection with magnetic resonance imaging. Atherosclerosis (in press)
50. Schmitz SA, Coupland SE, Gust R, Winterhalter S, Wagner S, Kresse M, et al. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest Radiol 2000;35:460-71
51. Ruehm SG, Corot C, Vogt P, Cristina H, Debatin JF. Ultrasmall superparamagnetic iron oxide-enhanced MR imaging of atherosclerotic plaque in hyperlipidemic rabbits. Acad Radiol 2002;9 Suppl 1:S143-4
52. Trivedi R, U-King-Im J, Gillard J. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaque. Circulation 2003;108:e140; author reply e140
53. Kooi ME, Cappendijk VC, Cleutjens KB, Kessels AG, Kitslaar PJ, Borgers M, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003;107:2453-8
54. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res 2005;96:327-36
55. Hamilton AJ, Huang SL, Warnick D, Rabbat M, Kane B, Nagaraj A, et al. Intravascular ultrasound molecular imaging of atheroma components in vivo. J Am Coll Cardiol 2004;43:453-60
56. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976;193:1007-8
57. Gaffen SL, Liu KD. Overview of interleukin-2 function, production and clinical applications. Cytokine 2004;28:109-23
58. Okopien B, Krysiak R, Kowalski J, Madej A, Belowski D, Zielinski M, et al. The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis 2004;176:327-35
59. Signore A, Chianelli M, Annovazzi A, Rossi M, Maiuri L, Greco M, et al. Imaging active lymphocytic infiltration in coeliac disease with iodine-123-interleukin-2 and the response to diet. Eur J Nucl Med 2000;27:18-24
60. 99mTc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease. Eur J Nucl Med Mol Imaging 2003;30:374-82